CTHRC1 and pulmonary fibrosis: Since CTHRC1-positive fibroblasts are implicated in the progression of fibrosis in COVID-19 patients, these findings raised the possibility of including pirfenidone within a standard treatment protocol to improve the outcome of post-COVID-19 lung fibrosis patients.